Neoadjuvant pembrolizumab does not increase surgical complications in oral cavity cancer

DALLAS — Neoadjuvant pembrolizumab did not increase risk for serious surgical complications among patients with advanced oral cavity cancer, study results presented at American Head & Neck Society Annual Meeting showed.
In addition, neoadjuvant pembrolizumab can potentially reduce perioperative morbidity given immediate tumor response prior to surgical resection.
“A lot of us have been suspicious that perhaps immunotherapy could cause poor wound healing, and this contradicts other data that have already been published,” Alice L. Tang, MD, assistant professor at University

DALLAS — Neoadjuvant pembrolizumab did not increase risk for serious surgical complications among patients with advanced oral cavity cancer, study results presented at American Head & Neck Society Annual Meeting showed.
In addition, neoadjuvant pembrolizumab can potentially reduce perioperative morbidity given immediate tumor response prior to surgical resection.
“A lot of us have been suspicious that perhaps immunotherapy could cause poor wound healing, and this contradicts other data that have already been published,” Alice L. Tang, MD, assistant professor at University